Astatine-211 Solution Purification Using Reducing Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for producing astatine-211 solutions result in low radiochemical purity, leading to weak accumulation of radioactivity in the thyroid gland during in vivo experiments, limiting their effectiveness in radiotherapy.
Innovation Solution
A production method involving the addition of a reducing agent, such as ascorbic acid, to astatine-211 solutions to enhance radiochemical purity, resulting in improved accumulation of radioactivity in the thyroid gland.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to produce astatine-211 solutions, then the production process is simple, but the radiochemical purity is low
Solution Approach 1:
The patent introduces a reducing agent as an intermediary substance that mediates between the astatine-211 and impurities. The reducing agent selectively reduces impurities while leaving astatine-211 unchanged, thereby purifying the solution without requiring complex separation equipment or multi-step processes.
Solution Approach 2:
The patent changes the chemical parameter of the solution by adding a reducing agent, which alters the oxidation state of impurities. This parameter change enables selective reduction of impurities to a different chemical form that can be easily separated, thereby improving radiochemical purity through a relatively simple process modification.
2Reliability
If astatine-211 solutions with low radiochemical purity are used, then the production method is simple, but the accumulation of radioactivity in the thyroid gland is weak
Solution Approach 1:
The reducing agent acts as a mediator that selectively interacts with impurities, converting them into forms that do not accumulate in the thyroid gland. This ensures that only the astatine-211 accumulates in the thyroid, improving both reliability and purity simultaneously.
Solution Approach 2:
The patent converts the harmful effect of impurities (which cause non-specific accumulation) into a beneficial separation process. By using the reducing agent, impurities are transformed into substances that can be easily removed, turning the problem of impurity presence into an opportunity for selective purification.
3Reliability
If astatine-211 solutions with low radiochemical purity are used, then the production cost is low, but the effectiveness of radiotherapy is limited
Solution Approach 1:
The reducing agent serves as a cost-effective intermediary that enables purification without requiring expensive complex equipment or multi-step processes. This allows production of high-purity astatine-211 solutions at reasonable costs, improving radiotherapy effectiveness while maintaining economic feasibility.
Solution Approach 2:
By changing the chemical parameter of the solution through addition of a reducing agent, the patent achieves high radiochemical purity through a simple one-step process. This parameter change enables effective radiotherapy while avoiding the need for complex, expensive purification systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces astatine-211 solutions with a radiochemical purity of not less than 50%, enhancing radioactivity accumulation in the thyroid gland and reducing non-specific accumulation in other organs, thereby improving the effectiveness of radiotherapy.
Implementation Method 1
a step of adding a reducing agent to an aqueous solution, ethanol solution, ethanol aqueous solution containing impurity derived from 211At
Data Source
Figure 1(a)~1(d)
Figure 2~3
Figure 4~5
AI summary
The present invention aims to provide an astatine solution that can be used in RI internal radiotherapy and the like for the treatment of thyroid gland disease and the like, and a production method thereof. The present invention provides a method for producing a solution containing 211At- (astatide ion) at a high radiochemical purity by using 211At obtained by a nuclear reaction as a starting material, including a step of adding a reducing agent to a solution containing an impurity derived from 211At; and a solution containing 211At- (astatide ion) at a radiochemical purity of not less than 30%.